Safety and Effectiveness of Ruxolitinib Cream in Kids and Adults with Hidradenitis Suppurativa

In this study we want to learn about how safe and how well a new skin cream works to treat children with a skin condition called hidradenitis suppurativa.


Why this Research Matters

Hidradenitis suppurative (HS) is a medical condition that can cause painful and itchy bumps in the folds of your skin. In this study we are comparing how well the study cream (called ruxolitinib) works compared to a vehicle cream. A vehicle cream looks and is used like ruxolitinib but has no active parts. This study has two parts. In the first part, you/your child will be randomly assigned to use either ruxolitinib or the vehicle cream, like flipping a coin. In the second part, all people in the study will use ruxolitinib. If you/your child join this study, you will come to 13 study visits at Children's Hospital Colorado. There will be 4 more study visits over the phone. You/your child's participation in the study will last for about 14 months. During the in-person study visits, we will do physical exams and ask you questions about your health. We will use a needle in your arm to collect blood samples. We may also ask you to give urine samples. When you/your child are at home in between study visits, we will ask you to keep track of your HS symptoms and to keep a log of when you apply the study cream. You/your child will be paid $100 for each study visit that you complete.


Who can Participate

Adult

You/your child may be able to join this study if you are at least 12 years old and have been diagnosed with hidradenitis suppurative. You/your child must also be willing to not use antibiotics or topical antiseptics to treat your HS during your time in the study. If you/your child are interested in joining our study, we will do other tests to make sure you meet other requirements and that it is safe for you to join.


Study ID

Protocol Number: 25-0917


Compensation Information

Compensation
Study Payment: Compensation provided.

Meet the Team

Image of Principal Investigator

Emily Gorell, DO

Principal Investigator